We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

1 hedge funds and large institutions have $75 invested in Oncternal Therapeutics, Inc. Common Stock in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $74 → $75 (+$1)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ONCT Hedge Fund Activity: Q2 2026 in Review

1 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2026, worth a combined $75 — up 1.4% from $74 a quarter earlier.

Fund positioning in ONCT was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $75 of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2026, up 1.4% quarter-over-quarter.
  • 0 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2026 and 0 closed out.

Based on aggregated 13F filings for Q2 2026.